Published in J Acquir Immune Defic Syndr on February 01, 2003
Pericardial Fat and Inflammation in HIV Patients and Controls | NCT02399384
Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr (2010) 2.47
Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. J Infect Dis (2009) 2.20
State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation (2008) 2.17
C-reactive protein independently predicts HIV-related outcomes among women and children in a resource-poor setting. AIDS (2007) 1.39
Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir. AIDS (2012) 1.34
Soluble biomarkers and morbidity and mortality among people infected with HIV: summary of published reports from 1997 to 2010. Curr Opin HIV AIDS (2010) 1.09
Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202. J Acquir Immune Defic Syndr (2014) 1.06
Markers of atherosclerosis and inflammation and mortality in patients with HIV infection. Atherosclerosis (2010) 1.05
Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals. AIDS Res Hum Retroviruses (2010) 1.04
Low serum albumin and the acute phase response predict low serum selenium in HIV-1 infected women. BMC Infect Dis (2006) 1.00
The Relationship Between HIV Infection and Cardiovascular Disease. Curr Cardiol Rev (2008) 0.94
Serum 25-hydroxyvitamin d levels and C-reactive protein in persons with human immunodeficiency virus infection. AIDS Res Hum Retroviruses (2012) 0.90
Inflammatory Markers Associated with Coronary Heart Disease in Persons with HIV Infection. Curr Infect Dis Rep (2011) 0.90
Usefulness of alternate prognostic serum and plasma markers for antiretroviral therapy for human immunodeficiency virus type 1 infection. Clin Vaccine Immunol (2007) 0.89
A pilot study of telmisartan for visceral adiposity in HIV infection: the metabolic abnormalities, telmisartan, and HIV infection (MATH) trial. PLoS One (2013) 0.87
Metabolic syndrome predicts all-cause mortality in persons with human immunodeficiency virus. AIDS Patient Care STDS (2013) 0.83
Changes in the levels of some acute-phase proteins in human immunodeficiency virus-1 infected patients, following interleukin-2 treatment. Clin Exp Immunol (2010) 0.78
Prevention of atherosclerosis in patients living with HIV. Vasc Health Risk Manag (2009) 0.77
Evaluating health and disease in Sub-Saharan Africa: minimally invasive collection of plasma in the Malawi Longitudinal Study of Families and Health (MLSFH). Genus (2012) 0.76
Immune activation markers in peripartum women in Botswana: association with feeding strategy and maternal morbidity. PLoS One (2014) 0.76
An Evaluation of Alternative Markers to Guide Initiation of Anti-retroviral Therapy in HIV-Infected Children in Settings where CD4 Assays are not Available. J Trop Pediatr (2015) 0.75
Effect of Recombinant Human Growth Hormone and Rosiglitazone for HIV-Associated Abdominal Fat Accumulation on Adiponectin and other Markers of Inflammation. HIV Clin Trials (2016) 0.75
Role of high-sensitivity C-reactive protein measurements in HIV patients. Indian J Sex Transm Dis (2016) 0.75
The Women's Interagency HIV Study: an observational cohort brings clinical sciences to the bench. Clin Diagn Lab Immunol (2005) 7.30
Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst (2005) 5.29
The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy. Ann Intern Med (2004) 3.05
Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. J Natl Cancer Inst (2003) 2.81
Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Natl Cancer Inst (2004) 2.23
Association of cigarette smoking with HIV prognosis among women in the HAART era: a report from the women's interagency HIV study. Am J Public Health (2006) 2.19
Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 2.11
Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy. Am J Med (2002) 2.11
Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS (2007) 2.10
Effects of bacterial vaginosis and other genital infections on the natural history of human papillomavirus infection in HIV-1-infected and high-risk HIV-1-uninfected women. J Infect Dis (2005) 2.04
Eligibility criteria for HIV clinical trials and generalizability of results: the gap between published reports and study protocols. AIDS (2005) 2.03
Marginal and mixed-effects models in the analysis of human papillomavirus natural history data. Cancer Epidemiol Biomarkers Prev (2010) 2.00
The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women. J Acquir Immune Defic Syndr (2005) 1.96
Pregnancy rates and predictors of conception, miscarriage and abortion in US women with HIV. AIDS (2004) 1.94
Risk factors for acquisition and clearance of oral human papillomavirus infection among HIV-infected and HIV-uninfected adults. Am J Epidemiol (2014) 1.88
Incidence of cervical squamous intraepithelial lesions associated with HIV serostatus, CD4 cell counts, and human papillomavirus test results. JAMA (2005) 1.86
Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr (2003) 1.78
HIV-1 in genital tract and plasma of women: compartmentalization of viral sequences, coreceptor usage, and glycosylation. Proc Natl Acad Sci U S A (2003) 1.71
Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy. Clin Infect Dis (2011) 1.70
Risk factors for oral HPV infection among a high prevalence population of HIV-positive and at-risk HIV-negative adults. Cancer Epidemiol Biomarkers Prev (2011) 1.68
Total lymphocyte count, hemoglobin, and delayed-type hypersensitivity as predictors of death and AIDS illness in HIV-1-infected women receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2004) 1.66
Changes in sexual behavior among HIV-infected women after initiation of HAART. Am J Public Health (2004) 1.59
Prevalence and predictors of Toxoplasma seropositivity in women with and at risk for human immunodeficiency virus infection. Clin Infect Dis (2002) 1.59
Serum immunoglobulin G response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and risk-matched HIV-negative women. J Infect Dis (2003) 1.57
The association of serum ferritin and transferrin receptor concentrations with mortality in women with human immunodeficiency virus infection. Haematologica (2006) 1.53
Functional attributes of mucosal immunity in cervical intraepithelial neoplasia and effects of HIV infection. Cancer Res (2004) 1.50
Czech health two decades on from the Velvet Revolution. Lancet (2009) 1.49
Live birth patterns among human immunodeficiency virus-infected women before and after the availability of highly active antiretroviral therapy. Am J Obstet Gynecol (2007) 1.48
Relationship between prevalent oral and cervical human papillomavirus infections in human immunodeficiency virus-positive and -negative women. J Clin Microbiol (2006) 1.46
Methicillin-resistant Staphylococcus aureus necrotizing pneumonia arising from an infected episiotomy site. Obstet Gynecol (2007) 1.46
Higher tenofovir exposure is associated with longitudinal declines in kidney function in women living with HIV. AIDS (2016) 1.45
A low-effort, clinic-wide intervention improves attendance for HIV primary care. Clin Infect Dis (2012) 1.42
Long-term incidence of cervical cancer in women with human immunodeficiency virus. Cancer (2009) 1.42
Challenging the strategy of maternal age-based prenatal genetic counseling. JAMA (2006) 1.41
Factors associated with preclinical disability and frailty among HIV-infected and HIV-uninfected women in the era of cART. J Womens Health (Larchmt) (2009) 1.41
The role of injection drug use in the emergence of Human Immunodeficiency Virus infection in Estonia. Int J Infect Dis (2002) 1.38
Outcomes after treatment of cervical intraepithelial neoplasia among women with HIV. J Low Genit Tract Dis (2007) 1.37
Prevalence and correlates of highly active antiretroviral therapy switching in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr (2002) 1.35
Retention and attendance of women enrolled in a large prospective study of HIV-1 in the United States. J Womens Health (Larchmt) (2009) 1.33
Factors and temporal trends associated with highly active antiretroviral therapy discontinuation in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr (2005) 1.31
Obesity and immune cell counts in women. Metabolism (2007) 1.31
Effect of antiretroviral therapy on the incidence of genital warts and vulvar neoplasia among women with the human immunodeficiency virus. Am J Obstet Gynecol (2004) 1.30
CC chemokine receptor 5 genotype and susceptibility to transmission of human immunodeficiency virus type 1 in women. J Infect Dis (2003) 1.29
Specific human leukocyte antigen class I and II alleles associated with hepatitis C virus viremia. Hepatology (2010) 1.28
The occurrence of vaginal infections among HIV-infected and high-risk HIV-uninfected women: longitudinal findings of the women's interagency HIV study. J Acquir Immune Defic Syndr (2006) 1.24
Antiretroviral therapy exposure and insulin resistance in the Women's Interagency HIV study. J Acquir Immune Defic Syndr (2008) 1.22
Low incidence of invasive cervical cancer among HIV-infected US women in a prevention program. AIDS (2004) 1.21
Contraceptive use among U.S. women with HIV. J Womens Health (Larchmt) (2007) 1.20
Depressive symptoms in the immediate postpartum period among Hispanic women in three U.S. cities. J Immigr Health (2004) 1.19
Serum albumin is a powerful predictor of survival among HIV-1-infected women. J Acquir Immune Defic Syndr (2003) 1.16
Effect of clinical-decision support on documentation compliance in an electronic medical record. Obstet Gynecol (2009) 1.14
The relation of HLA genotype to hepatitis C viral load and markers of liver fibrosis in HIV-infected and HIV-uninfected women. J Infect Dis (2011) 1.13
Anal intraepithelial neoplasia in a multisite study of HIV-infected and high-risk HIV-uninfected women. AIDS (2009) 1.12
Herpes simplex virus infection in women in the WIHS: epidemiology and effect of antiretroviral therapy on clinical manifestations. AIDS (2006) 1.11
Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women. J Acquir Immune Defic Syndr (2009) 1.10
HIV as a risk factor for lung cancer in women: data from the Women's Interagency HIV Study. J Clin Oncol (2010) 1.09
Predictors of reported influenza vaccination in HIV-infected women in the United States, 2006-2007 and 2007-2008 seasons. Prev Med (2010) 1.08
Hormonal contraceptive use and the effectiveness of highly active antiretroviral therapy. Am J Epidemiol (2005) 1.06
Risk of cervical precancer and cancer among HIV-infected women with normal cervical cytology and no evidence of oncogenic HPV infection. JAMA (2012) 1.06
The impact of HAART on the respiratory complications of HIV infection: longitudinal trends in the MACS and WIHS cohorts. PLoS One (2013) 1.06
HIV replication alters the composition of extrinsic pathway coagulation factors and increases thrombin generation. J Am Heart Assoc (2013) 1.04
Maternal-infant perinatal transmission of methicillin-resistant and methicillin-sensitive Staphylococcus aureus. Am J Perinatol (2008) 1.04
Permissive and protective factors associated with presence, level, and longitudinal pattern of cervicovaginal HIV shedding. J Acquir Immune Defic Syndr (2012) 1.03
Relative time to pregnancy among HIV-infected and uninfected women in the Women's Interagency HIV Study, 2002-2009. AIDS (2011) 1.02
Relation of stavudine discontinuation to anthropometric changes among HIV-infected women. J Acquir Immune Defic Syndr (2007) 1.02
Determinants of women's choice of obstetrician/gynecologist. J Womens Health Gend Based Med (2002) 1.01
Risk factors for Kaposi's sarcoma-associated herpesvirus infection among HIV-1-infected pregnant women in the USA. AIDS (2003) 1.00
Variants of human papillomaviruses 16 and 18 and their natural history in human immunodeficiency virus-positive women. J Gen Virol (2005) 1.00
Variations in serum müllerian inhibiting substance between white, black, and Hispanic women. Fertil Steril (2008) 0.99
HPV testing for triage of HIV-infected women with papanicolaou smears read as atypical squamous cells of uncertain significance. J Womens Health (Larchmt) (2004) 0.99
Pain and other symptoms in ambulatory HIV patients in the age of highly active antiretroviral therapy. J Assoc Nurses AIDS Care (2002) 0.98
Lymphoid follicles are generated in high-grade cervical dysplasia and have differing characteristics depending on HIV status. Am J Pathol (2002) 0.97
In utero marijuana exposure associated with abnormal amygdala dopamine D2 gene expression in the human fetus. Biol Psychiatry (2004) 0.97
Circulating vitamin D correlates with serum antimüllerian hormone levels in late-reproductive-aged women: Women's Interagency HIV Study. Fertil Steril (2012) 0.96
Effects of HIV infection and its treatment on self-reported menstrual abnormalities in women. J Womens Health (Larchmt) (2006) 0.96
Predictors of H1N1 vaccination in pregnancy. Am J Obstet Gynecol (2011) 0.94
Plasma and mucosal HIV viral loads are associated with genital tract inflammation in HIV-infected women. J Acquir Immune Defic Syndr (2013) 0.94
Relationship between HIV viral load and Langerhans cells of the cervical epithelium. J Obstet Gynaecol Res (2005) 0.94
HIV tropism and decreased risk of breast cancer. PLoS One (2010) 0.94
The impact of HIV infection and immunodeficiency on human papillomavirus type 6 or 11 infection and on genital warts. Sex Transm Dis (2002) 0.93
Concomitant anal and cervical human papillomavirusV infections and intraepithelial neoplasia in HIV-infected and uninfected women. AIDS (2013) 0.93
Serological detection of human papillomavirus type 16 infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women. Clin Vaccine Immunol (2006) 0.93
Pulmonary symptoms and diagnoses are associated with HIV in the MACS and WIHS cohorts. BMC Pulm Med (2014) 0.93
Elevated NT-pro-BNP levels are associated with comorbidities among HIV-infected women. AIDS Res Hum Retroviruses (2009) 0.92
Natural history of grade 1 cervical intraepithelial neoplasia in women with human immunodeficiency virus. Obstet Gynecol (2004) 0.92
Genital tract HIV RNA levels and their associations with human papillomavirus infection and risk of cervical precancer. J Acquir Immune Defic Syndr (2014) 0.91
Correlates of prevalent hypertension in a large cohort of HIV-infected women: Women's Interagency HIV Study. AIDS (2007) 0.91
Human leukocyte antigen genotype and risk of HIV disease progression before and after initiation of antiretroviral therapy. J Virol (2011) 0.91
A C17T polymorphism in the mu opiate receptor is associated with quantitative measures of drug use in African American women. Addict Biol (2010) 0.91
Correlates of CD4+ and CD8+ lymphocyte counts in high-risk immunodeficiency virus (HIV)-seronegative women enrolled in the women's interagency HIV study (WIHS). Hum Immunol (2007) 0.91
Lower liver-related death in African-American women with human immunodeficiency virus/hepatitis C virus coinfection, compared to Caucasian and Hispanic women. Hepatology (2012) 0.91
Immunogenicity of an inactivated monovalent 2009 influenza A (H1N1) vaccine in patients who have cancer. Oncologist (2012) 0.90
A longitudinal study of human papillomavirus 16 L1, e6, and e7 seropositivity and oral human papillomavirus 16 infection. Sex Transm Dis (2015) 0.89